H.C. Wainwright Thinks Karyopharm Therapeutics’ Stock is Going to RecoverBy Jason Carr
According to TipRanks.com, Deepak is ranked 0 out of 5 stars with an average return of -27.1% and a 24.1% success rate. Deepak covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, Mirna Therapeutics Inc, and Fate Therapeutics.
Currently, the analyst consensus on Karyopharm Therapeutics is Strong Buy and the average price target is $18, representing a 179.9% upside.
In a report issued on October 31, Jefferies also reiterated a Buy rating on the stock with a $12 price target.
The company has a one year high of $19.41 and a one year low of $4.83. Currently, Karyopharm Therapeutics has an average volume of 431.3K.
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is neutral on the stock. Most recently, in June 2016, Chione Ltd, a Major Shareholder at KPTI sold 18,824 shares for a total of $150,968.
Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company. It is focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. Its selective inhibitors of nuclear export compounds function by preventing the export of tumor suppressor proteins from the nucleus of a cell. Karyopharm Therapeutics was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.